PD-1 axis binding antagonist, platinum agent, and method of treating lung cancer using topoisomerase II inhibitor

摘要

The present disclosure provides a method of treating lung cancer in a subject (eg, small cell lung cancer, such as an expanded stage small cell lung cancer). The method includes a PD-1 axis binding antagonist (e.g., an anti-PD-L1 antibody such as atezolizumab), a platinum agent (e.g., cisplatin or carboplatin), and a topoisomerase II inhibitor (e.g., Eto Posid) to the subject.